New transplant strategy aims to stop devastating immune reaction
NCT ID NCT06265584
Summary
This study is testing whether changing the timing of a standard immune-suppressing drug (ATG) can better prevent severe graft-versus-host disease (GVHD) after a stem cell transplant. The trial will enroll 56 adults with acute leukemia, myelodysplastic syndrome, or myeloproliferative disorders who are receiving a reduced-intensity transplant. Researchers hope this approach will prevent severe GVHD while still allowing the donor cells to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.